Overall Perfomance for "Broad Street Alerts"
The following three charts can be used by potential investors to gauge the performance of "Broad Street Alerts":
0 out of 1 campaigns closed down on first day
1 out of 1 campaigns closed up on first day
0 out of 1 campaigns had no net effect
ATNM Promotional Newsletter
The following is a newsletter released by "Broad Street Alerts" promoting Actinium Pharmaceuticals, Inc.
One of our favorites is on the move...
Actinium ATNM Three Full Analysts Reports
Morning Gap Filled and Moving Back Up
The analysts projections indicate ATNM could grow in value in the near to mid-term
Good day everyone,
We are continuing our coverage of, Actinium Pharmaceuticals, Inc. NYSE ATNM, a clinical stage biopharmaceutical company.
Current price $11.70 per share
ATNM shares opened strong in Thursdays session quickly gaining to $12.05 per share before retracting to the current price 3.63%.
Today, we are including links to comprehensive reports from three different analysts. Look and see why these analysts are issuing target prices from $25 to $65 per share. All these analysts reports were published about a week ago.
Maxim Group This analysts report has a good summary of the more clinically advanced products in the ATNM pipeline. Maxim rates ATNM shares a buy and suggests potential commercialization dates for the companys products.
William Blair ATNM may have sufficient cash to fund operations and clinical studies until H2 2021. This analysis will explain why. This analyst looks at the potential milestones including those reported by the company this week contained in the ATNM pipeline. This analyst rates ATNM shares as outperform.
H.C. Wainwright Co. Read about the analysts forecast indicating the potential for Actinium to achieve a market cap more than $1 billion. This report looks extensively at the ATNM pipeline. This analysis reiterates the HCW buy rating for ATNM shares.
The three of the ATNM press releases we discussed in our earlier newsletter could be transformative for Actinium. As the companys pipeline continues to expand, with other pharma partners participating, and data from clinical studies continue to look positive, the companys visibility will grow as well.
It is that increased visibility in the biopharma sector that could help to grow the company to a market cap comparable with its peers.
The American Society of Hematology ASH will host its 62nd annual meeting December 5-8. Like many functions in 2020, this years ASH conference will be virtual. ATNM has been approved for three oral and one poster presentations.
Sandesh Seth, Actinium's Chairman and CEO. We look forward to presenting the Iomab-B data in further detail during the two oral presentations on the Iomab-B SIERRA study at ASH in December. The company remains on track to report safety and feasibility data from 75% of the patients to be enrolled in SIERRA, as well as to complete the ad hoc interim analysis in the fourth quarter.
Actinium has no debt. While the company operates at a net loss, the data from their Q3 2020 10-Q filing indicates that earnings may be headed in a direction toward profitability.
The tiny number of shares in the public float 12.34M can have a significant impact on the company share price particularly when considering the overall market cap of the company. A share price of $20, for example, would only yield a market cap of $270M, still much below the companys peers and not fully addressing the commercialization potential for the companys products.
The current quarter could be the transformative period for Actinium, particularly as regards to Iomab-B and the SIERRA clinical trial. The data being released, and the upcoming ASH presentations could elevate the company to a new level in the biopharma sector and we expect the company share price could also rise to a new level.
Actinium ATNM Issues Clinical Trial Data Sets
Good day everyone,
We are continuing our coverage of, Actinium Pharmaceuticals, Inc. NYSE ATNM, a clinical stage biopharmaceutical company.
Current price $11.24 per share
Its been two weeks since we last talked about Actinium. ATNM shares opened at $11.17 per share on Wednesday, October 21, 2020, and quickly gained 8.5% to $12.12share.
So why are we reporting on ATNM again There are two reasons. The share price appears to be a value just as it was two weeks ago, and the company has just provided important corporate updates.
On Wednesday, November 4th, ATNM released three press releases with important updates on three of its clinical studies. We have summarized the news and provided links to the full press releases below
100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML - 70% of patients achieving remission were MRD-negative with remissions and MRD negativity reported in all dose cohorts. Data to be presented in an oral presentation at the 62nd American Society of Hematology Annual Meeting.
Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting - Universal rates of BMT and engraftment continue in Phase 3 SIERRA pivotal trial in relapsedrefractory AML for all patients receiving therapeutic dose of Iomab-B. Second oral presentation to showcase lower rates of sepsis, infections, and mucositis for Iomab-B patients compared to control arm.
Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting - There were no DLTs in first dose cohort, combination advances to additional dose cohorts in RR AML patients. Encouraging initial response observed with subtherapeutic doses of Actimab-A support potential mechanistic synergy with venetoclax.
On October 28, 2020, the company updated investors with the progress in its clinical trials and the news is encouraging indicating multiple milestones that may be achieved in the next seven weeks.
Iomab-B SIERRA Pivotal Trial-The SIERRA trial reached seventy-five percent enrollment. The Company will report safety and feasibility data from 75% enrollment in the Fourth Quarter see news above.
Actimab-A and CLAG-M Phase 1 Combination Trial-Successfully completed third and final dose cohort of 1.0 uCiKg of Actimab-A marking the completion of the planned Phase 1 trial. The Company expects to present results from the third dosing cohort in the Phase 1 trial in the fourth quarter of 2020 see news above.
Actimab-A and Venetoclax Phase 12 Combination Trial -Successfully completed first dosing cohort thus allowing the study to proceed to a second dose cohort of 1.0 uCiKg Actimab-A and venetoclax combination. First in human data expected in Q4 2020 see news above.
Iomab-ACT CAR-T Program -Actinium was awarded a Fast-Track Phase 12 STTR grant by the National Institutes of Health NIH for a clinical collaboration of Iomab-ACT targeted conditioning with Memorial Sloan Kettering Cancer Center's MSK CD19 CAR T-Cell therapy, 19-28z.
We have included the following link in case you want to read the entire investor update
Actinium reported a cash balance of $48.2 million as of September 30, 2020. The current cash balance as of October 28th is expected to fund operations through clinical milestones including completion of the Pivotal Phase 3 SIERRA trial, completion of ongoing Phase 12 Actimab-A combination trials and planned RD activity.
It is our belief that the value from the success of the ATNM clinical trials may not yet be built into the share pricemarket cap. The Iomab-B SIERRA Pivotal Trial has been the top story at ATNM for a long time and while the recent news from that trial is encouraging, investors may feel the value of that study is already built into the share price.
Actinium has 12 products in development, some in clinical trials and some in pre-clinical development. Its the potential value of these products that could be missing from the current market cap.
The ATNM market cap currently at $152M. Keep in mind that the company may likely be sitting on $40M in cash, which leaves $100M as speculative market value. We want to reiterate the comparison below showing the ATNM market cap lags its peers, in many cases, by a factor of 3.0X.
Lets look at some developmental biopharma companies, similar in scope to Actinium, to see how their market caps compare
XBiotech XBIT $548M
Atreca BCEL $525M
Applied Therapeutics APLT $485M
Odonate Therapeutics ODT $599M
Marinus Pharma MRNS $445M
Viking Therapeutics VKTX $408M
Near term catalysts for ATNM shares
Consolidated share price 47% off 52-week high
Small share structure only 12.34M shares in the float
Data sets from clinical trials just released.
Mid-term catalysts for ATNM shares
Potential collaborations with big pharma companies.
A cash raise seems unlikely over the mid-term.
A review of the chart setup linked below indicates shares that may be oversold. The current price is well above the 50 and 200 DMAs indicating the shares may be trending in breakout territory.
We will be back with more soon,
Do we disclose any information to outside parties
We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect
We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.
When registering on our site, as appropriate, you may be asked to enter your e-mail address
What do we use your information for
When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, andor other requests or questions.
How do we protect your information
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
This websitenewsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reportsreleases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our emailblog list as well as any social networking platforms we may use.
PLEASE NOTE WELL SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury monetary or otherwise that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions quote may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. SCS LLC has been co.mpensated twenty three thousand three hundred thirty three dollars cas.h via bank wir.e by legends media llc for this week and our previous week of coverage on atnm. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.
Copyright 2020 Broad Street Alerts,
Last 1 Stock Promotions By "Broad Street Alerts"
|JETR||Star Jets International, Inc.||September 24, 2020||0.140||59%|